- Home
- GANX vs ASPS Comparison
GANX vs ASPS Comparison
Compare GANX & ASPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GANX | ASPS |
|---|---|---|
| Founded | 2017 | 1999 |
| Country | United States | Luxembourg |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Consumer Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 74.6M | 81.5M |
| IPO Year | 2021 | 2025 |
Fundamental Metrics
Financial Performance| Metric | GANX | ASPS |
|---|---|---|
| Price | $1.70 | $5.11 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | $7.50 | ★ $8.00 |
| AVG Volume (30 Days) | ★ 629.3K | 22.7K |
| Earning Date | 05-13-2026 | 04-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 31.46 | ★ 112.00 |
| EPS | N/A | ★ N/A |
| Revenue | $55,180.00 | ★ $942,213,000.00 |
| Revenue This Year | N/A | $9.17 |
| Revenue Next Year | N/A | $24.26 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.41 | $4.30 |
| 52 Week High | $4.34 | $14.36 |
Technical Indicators
Market Signals| Indicator | GANX | ASPS |
|---|---|---|
| Relative Strength Index (RSI) | 45.61 | 29.63 |
| Support Level | $1.65 | $5.00 |
| Resistance Level | $2.15 | $7.35 |
| Average True Range (ATR) | 0.12 | 0.39 |
| MACD | -0.00 | -0.16 |
| Stochastic Oscillator | 36.60 | 14.58 |
Price Performance
Historical ComparisonAbout GANX Gain Therapeutics Inc.
Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.
About ASPS Altisource Portfolio Solutions S.A.
Altisource Portfolio Solutions SA is an integrated service provider and marketplace for the real estate and mortgage industries. It operates via two reportable segments, namely Servicer and Real Estate, which derive maximum revenue, and Origination. The Servicer and Real Estate segment provides loan servicers and real estate investors with solutions and technologies that span the mortgage and real estate lifecycle. The Origination segment provides originators with solutions and technologies that span the mortgage origination lifecycle. Altisource mainly serves financial institutions, government-sponsored enterprises, and originators in the United States, with the majority of its revenue flowing from field services and mortgage and real estate solutions.